Saghmos Therapeutics
A privately held pharmaceutical company developing therapies for life-threatening cardiovascular and renal diseases with unmet medical needs.
Saghmos’ lead product, ST-62516 (trimetazidine), is poised to enter a Phase III study as of Q3 2023 to reduce the risk of Major Adverse Cardiac and Kidney Events (MACKE) after percutaneous coronary intervention (PCI) procedures in patients with unstable angina.
Latest Saghmos Therapeutics News & Features
4 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze